Business context and reporting period
The supplied filing is Onconova Therapeutics, Inc.’s unaudited Form 10-Q for the quarter ended March 31, 2023, not a filing identified as Traws Pharma, Inc. It reports a clinical-stage oncology business with narazaciclib and rigosertib programs. The company’s common stock traded as ONTX on Nasdaq.
Key financial metrics
| Metric | Q1 2023 / March 31, 2023 | Comparable period / December 31, 2022 |
|---|---|---|
| Revenue | $56,000 | $56,000 in Q1 2022 |
| Research and development expense | $4.080 million | $2.002 million in Q1 2022 |
| General and administrative expense | $2.113 million | $2.186 million in Q1 2022 |
| Net loss | $5.775 million; $0.28 per share | $4.122 million; $0.20 per share in Q1 2022 |
| Cash used in operating activities | $4.543 million | $4.296 million in Q1 2022 |
| Cash and cash equivalents | $34.220 million | $38.757 million at December 31, 2022 |
| Working capital | $25.8 million | Not stated for the comparable date |
| Total liabilities | $12.185 million | $11.063 million at December 31, 2022 |
| Accumulated deficit | $469.458 million | $463.683 million at December 31, 2022 |
The filing reports no interest-bearing debt on the balance sheet; liabilities primarily comprise accounts payable, accrued expenses, and deferred revenue. A conventional operating margin is not informative given the company’s minimal collaboration revenue and development-stage operations.
Material changes versus prior period
- Net loss widened by $1.653 million year over year, mainly as R&D expense increased $2.078 million. The company attributed the R&D increase primarily to narazaciclib clinical development, manufacturing timing, and higher personnel costs.
- Other income increased to $362,000 from $10,000, principally due to higher interest income, partly offset by foreign-exchange losses.
- Cash declined by $4.537 million during Q1 2023. Operating cash use was modestly higher than the $4.296 million used in Q1 2022.
- Deferred revenue from the SymBio collaboration was $3.187 million at March 31, 2023; $56,000 was recognized as revenue in the quarter.
Outlook, commentary, risks, and unusual items
- Management estimated existing cash would fund ongoing trials and operations into the first quarter of 2024, but not for at least 12 months after issuance of the financial statements. The company concluded that substantial doubt exists about its ability to continue as a going concern and said additional financing is required.
- Management plans to pursue dilutive and non-dilutive funding, including equity financing, strategic alliances, and business-development arrangements. No assurance was given that financing will be available on acceptable terms or at all; failure to secure capital could materially harm operations.
- Management expects 2023 cash expenditures to exceed 2022 levels, citing narazaciclib trials and increased clinical and regulatory headcount. Potential in-licensing could add costs.
- Narazaciclib: the U.S. Phase 1 solid-tumor study’s 200 mg cohort was complete with one dose-limiting toxicity; the 240 mg cohort was ongoing. A Phase 1/2a narazaciclib-plus-letrozole trial for recurrent metastatic low-grade endometrioid endometrial cancer began in Q1; the first patient was dosed in May 2023.
- Rigosertib: an investigator-initiated study in checkpoint-inhibitor-resistant, KRAS-mutated NSCLC remained open and enrolling. Interim data previously reported responses in four of 14 evaluable patients; the filing anticipated additional data in the first half of 2023. A melanoma combination study opened for enrollment in March 2023. Rigosertib monotherapy data in RDEB-associated squamous cell carcinoma were described as encouraging but based on only two patients.
- Nasdaq continued-listing compliance was reported as current as of May 15, 2023, although the company disclosed prior periods of noncompliance and warned of possible future delisting. The filing reported no pending material legal proceedings.
Important facts for investors to verify
- Confirm the issuer: the provided document is Onconova Therapeutics, Inc. (ONTX), not Traws Pharma, Inc.
- Assess the going-concern disclosure, cash runway assumptions, quarterly cash burn, and prospects and terms for additional financing.
- Track clinical-trial enrollment, safety findings, and follow-up efficacy data, especially the narazaciclib dose-escalation and rigosertib studies.
- Verify current Nasdaq listing status and any subsequent financing, collaboration, or material clinical developments.